Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $134.93 in the prior trading day, Axsome Therapeutics Inc (NASDAQ: AXSM) closed at $135.69, up 0.56%. In other words, the price has increased by $0.56 from its previous closing price. On the day, 0.58 million shares were traded. AXSM stock price reached its highest trading level at $135.8 during the session, while it also had its lowest trading level at $131.68.
Ratios:
Our goal is to gain a better understanding of AXSM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.57. In the meantime, Its Debt-to-Equity ratio is 2.96 whereas as Long-Term Debt/Eq ratio is at 1.97.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on October 01, 2025, initiated with a Buy rating and assigned the stock a target price of $179.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 05 ’25 when Herriot Tabuteau bought 21,775 shares for $135.69 per share.
TABUTEAU HERRIOT sold 91,705 shares of AXSM for $12,136,240 on Nov 03 ’25. The Chief Executive Officer now owns 7,229 shares after completing the transaction at $132.34 per share. On Nov 04 ’25, another insider, TABUTEAU HERRIOT, who serves as the Chief Executive Officer of the company, sold 50,459 shares for $133.79 each. As a result, the insider received 6,750,910 and left with 7,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 6840491008 and an Enterprise Value of 6733815296. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.19 while its Price-to-Book (P/B) ratio in mrq is 92.59. Its current Enterprise Value per Revenue stands at 11.998 whereas that against EBITDA is -35.828.
Stock Price History:
The Beta on a monthly basis for AXSM is 0.48, which has changed by 0.4876516 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, AXSM has reached a high of $139.13, while it has fallen to a 52-week low of $75.56. The 50-Day Moving Average of the stock is 9.40%, while the 200-Day Moving Average is calculated to be 18.67%.
Shares Statistics:
The stock has traded on average 526.96K shares per day over the past 3-months and 547510 shares per day over the last 10 days, according to various share statistics. A total of 50.31M shares are outstanding, with a floating share count of 41.59M. Insiders hold about 17.50% of the company’s shares, while institutions hold 76.05% stake in the company. Shares short for AXSM as of 1760486400 were 3437283 with a Short Ratio of 6.52, compared to 1757894400 on 3451398. Therefore, it implies a Short% of Shares Outstanding of 3437283 and a Short% of Float of 8.2100004.
Earnings Estimates
The stock of Axsome Therapeutics Inc (AXSM) is currently in the spotlight, with 4.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.55, with high estimates of -$0.22 and low estimates of -$0.83.
Analysts are recommending an EPS of between -$4.28 and -$4.28 for the fiscal current year, implying an average EPS of -$4.28. EPS for the following year is $0.57, with 11.0 analysts recommending between $3.78 and -$3.61.
Revenue Estimates
16 analysts predict $187.44M in revenue for. The current quarter. It ranges from a high estimate of $194.8M to a low estimate of $180.94M. As of. The current estimate, Axsome Therapeutics Inc’s year-ago sales were $118.77MFor the next quarter, 16 analysts are estimating revenue of $188.81M. There is a high estimate of $198.85M for the next quarter, whereas the lowest estimate is $177.94M.
A total of 20 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $637.3M, while the lowest revenue estimate was $505M, resulting in an average revenue estimate of $620M. In the same quarter a year ago, actual revenue was $385.69MBased on 20 analysts’ estimates, the company’s revenue will be $965.17M in the next fiscal year. The high estimate is $1.1B and the low estimate is $819M.
